1103500-32-8Relevant articles and documents
COMPOSITIONS AND METHODS FOR TREATING LIVER DISORDERS
-
Paragraph 0221, (2021/12/31)
The present disclosure is directed to FXR agonists, pharmaceutical compositions thereof, and methods of using the same for preventing, treating, or ameliorating fatty liver diseases such as steatosis, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis, either alone or in combination with thyroid receptor agonists.
Isoxazole FXR receptor agonist as well as preparation method and medical application thereof
-
Paragraph 0042-0044, (2021/07/14)
The invention belongs to the field of medicinal chemistry, and particularly relates to an isoxazole FXR receptor agonist and a preparation method and medical application thereof. The invention relates to a compound as shown in a formula (I), and pharmaceutically acceptable salts and isotope markers thereof. The compound as shown in the formula (I), the pharmaceutically acceptable salts and the isotope markers thereof have FXR receptor agonist activity and can be applied to preparation of drugs for treating or preventing hyperlipidemia, atherosclerosis, non-alcoholic steatohepatitis and type II diabetes mellitus.
PPARs-FXR multi-target micromolecular agonist as well as preparation method and application thereof
-
Paragraph 0092; 0095; 0097; 0143-0148, (2021/05/22)
The invention discloses a PPARs-FXR multi-target micromolecule agonist and a preparation method and application thereof, the structure is shown in a general formula I, and the definition of each substituent group is shown in the description and claims. Th